Edition:
India

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

79.50USD
2:29am IST
Change (% chg)

$0.80 (+1.02%)
Prev Close
$78.70
Open
$79.26
Day's High
$79.80
Day's Low
$78.18
Volume
295,404
Avg. Vol
689,408
52-wk High
$131.86
52-wk Low
$68.25

Select another date:

Wed, Aug 19 2020

U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive

The U.S. Food and Drug Administration rejected BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A citing the need for longer-term data, the drugmaker said on Wednesday, potentially pushing any approval out to 2022.

UPDATE 3-U.S. FDA rejects BioMarin hemophilia A gene therapy, shares dive

Aug 19 The U.S. Food and Drug Administration rejected BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A citing the need for longer-term data, the drugmaker said on Wednesday, potentially pushing any approval out to 2022.

U.S. FDA declines to approve Biomarin's gene therapy for bleeding disorder

Aug 19 The U.S. Food and Drug Administration has declined to approve BioMarin Pharmaceutical Inc's gene therapy for bleeding disorder hemophilia A, citing the need for two-year data on the therapy, the drugmaker said on Wednesday.

BRIEF-BioMarin Promotes Company Veteran Brian Mueller To Executive Vice President, CFO

* BIOMARIN PROMOTES COMPANY VETERAN, BRIAN R. MUELLER, TO EXECUTIVE VICE PRESIDENT, CFO Source text for Eikon: Further company coverage:

BRIEF-BioMarin Provides New Data from Study Of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

* BIOMARIN PROVIDES ADDITIONAL DATA FROM RECENT 4 YEAR UPDATE OF ONGOING PHASE 1/2 STUDY OF VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY FOR SEVERE HEMOPHILIA A IN LATE-BREAKING ORAL PRESENTATION AT WORLD FEDERATION OF HEMOPHILIA VIRTUAL SUMMIT Source text for Eikon: Further company coverage:

Select another date: